000086366 001__ 86366
000086366 005__ 20200716101556.0
000086366 0247_ $$2doi$$a10.3390/molecules24142583
000086366 0248_ $$2sideral$$a115024
000086366 037__ $$aART-2019-115024
000086366 041__ $$aeng
000086366 100__ $$aCalpe-López, Claudia
000086366 245__ $$aCannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms
000086366 260__ $$c2019
000086366 5060_ $$aAccess copy available to the general public$$fUnrestricted
000086366 5203_ $$aCurrently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that cannabidiol (CBD) could be a promising treatment for substance use disorders. In the present work, the authors describe the scarce preclinical and human research about the actions of CBD on the effects of stimulant drugs, mainly cocaine and methamphetamine (METH). Additionally, the possible mechanisms underlying the therapeutic potential of CBD on stimulant use disorders are reviewed. CBD has reversed toxicity and seizures induced by cocaine, behavioural sensitization induced by amphetamines, motivation to self-administer cocaine and METH, context- and stress-induced reinstatement of cocaine and priming-induced reinstatement of METH seeking behaviours. CBD also potentiated the extinction of cocaine- and amphetamine-induced conditioned place preference (CPP), impaired the reconsolidation of cocaine CPP and prevented priming-induced reinstatement of METH CPP. Observational studies suggest that CBD may reduce problems related with crack-cocaine addiction, such as withdrawal symptoms, craving, impulsivity and paranoia (Fischer et al., 2015). The potential mechanisms involved in the protective effects of CBD on addiction to psychostimulant drugs include the prevention of drug-induced neuroadaptations (neurotransmitter and intracellular signalling pathways changes), the erasure of aberrant drug-memories, the reversion of cognitive deficits induced by psychostimulant drugs and the alleviation of mental disorders comorbid with psychostimulant abuse. Further, preclinical studies and future clinical trials are necessary to fully evaluate the potential of CBD as an intervention for cocaine and methamphetamine addictive disorders.
000086366 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/PSI2017-83023-R
000086366 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000086366 590__ $$a3.267$$b2019
000086366 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b70 / 177 = 0.395$$c2019$$dQ2$$eT2
000086366 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b141 / 297 = 0.475$$c2019$$dQ2$$eT2
000086366 592__ $$a0.698$$b2019
000086366 593__ $$aPharmaceutical Science$$c2019$$dQ1
000086366 593__ $$aChemistry (miscellaneous)$$c2019$$dQ2
000086366 593__ $$aDrug Discovery$$c2019$$dQ2
000086366 593__ $$aPhysical and Theoretical Chemistry$$c2019$$dQ2
000086366 593__ $$aOrganic Chemistry$$c2019$$dQ2
000086366 593__ $$aAnalytical Chemistry$$c2019$$dQ2
000086366 593__ $$aMedicine (miscellaneous)$$c2019$$dQ2
000086366 593__ $$aMolecular Medicine$$c2019$$dQ3
000086366 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000086366 700__ $$aGarcía-Pardo, M. Pilar$$uUniversidad de Zaragoza
000086366 700__ $$aAguilar, María A.
000086366 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000086366 773__ $$g24, 14 (2019), 2583 [21 pp.]$$pMolecules$$tMolecules$$x1420-3049
000086366 8564_ $$s931340$$uhttps://zaguan.unizar.es/record/86366/files/texto_completo.pdf$$yVersión publicada
000086366 8564_ $$s109135$$uhttps://zaguan.unizar.es/record/86366/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000086366 909CO $$ooai:zaguan.unizar.es:86366$$particulos$$pdriver
000086366 951__ $$a2020-07-16-09:49:47
000086366 980__ $$aARTICLE